TERBINAFINE VS GRISEOFULVINA NELLA TERAPIA DELLE ONICOMICOSI DA DERMATOFITI

Translated title of the contribution: Terbinafine vs griseofulvin in the treatment of onychomycosis due to dermatophytes

M. La Placa, C. Stinchi, N. Venturo, R. Morelli, Antonella Tosti

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Griseofulvin has been for a long time the only available antifungal agent for the systemic therapy of onychomycosis. However, this drug requires long treatment yielding low success rates and frequent relapses combined with a relatively high incidence of side effects. recently terbinafine, a new antifungal agent which has been shown to be an effective treatment with short-term regimen for onychomycosis, has been introduced in Italy. In a comparative double-blind study the efficacy of terbinafine and griseofulvin in the treatment of onychomycosis bas been evaluated. Out of 9 patients affected by fingernail onychomycosis, 4 were treated with terbinafine at the dosage of 250 mg/day for 2 months and 5 with griseofulvin at the dosage of 1 g/day for 4 months. Of 29 patients affected by toenail onychomycosis, 14 were treated with terbinafine 250 mg/day for 4 months and 15 with griseofulvin 1 g/day for 9 months. In all cases follow-up was 6 months. All four patients with fingernail onychomycosis (100%) and 11 of the 14 patients with toenail onychomycosis (78.5%) treated with terbinafine were completely cured. Two patients with fingernail onychomycosis (40%) and 4 patients with toenail onychomycosis (26.5%) treated with griseofulvin were cured. The successful results obtained with terbinafine, with the absence of concomitant relapses or side effects, suggest this drug as an agent of choice in the treatment of onychomycosis.

Original languageItalian
JournalGiornale Italiano di Dermatologia e Venereologia
Volume129
Issue number4
StatePublished - Aug 19 1994
Externally publishedYes

Fingerprint

terbinafine
Griseofulvin
Onychomycosis
Arthrodermataceae
Nails
Therapeutics
Antifungal Agents
Recurrence

Keywords

  • griseofulvin
  • onychomychosis
  • terbinafine

ASJC Scopus subject areas

  • Dermatology

Cite this

TERBINAFINE VS GRISEOFULVINA NELLA TERAPIA DELLE ONICOMICOSI DA DERMATOFITI. / La Placa, M.; Stinchi, C.; Venturo, N.; Morelli, R.; Tosti, Antonella.

In: Giornale Italiano di Dermatologia e Venereologia, Vol. 129, No. 4, 19.08.1994.

Research output: Contribution to journalArticle

@article{443bdd3415c74377a5458b58e07e7a00,
title = "TERBINAFINE VS GRISEOFULVINA NELLA TERAPIA DELLE ONICOMICOSI DA DERMATOFITI",
abstract = "Griseofulvin has been for a long time the only available antifungal agent for the systemic therapy of onychomycosis. However, this drug requires long treatment yielding low success rates and frequent relapses combined with a relatively high incidence of side effects. recently terbinafine, a new antifungal agent which has been shown to be an effective treatment with short-term regimen for onychomycosis, has been introduced in Italy. In a comparative double-blind study the efficacy of terbinafine and griseofulvin in the treatment of onychomycosis bas been evaluated. Out of 9 patients affected by fingernail onychomycosis, 4 were treated with terbinafine at the dosage of 250 mg/day for 2 months and 5 with griseofulvin at the dosage of 1 g/day for 4 months. Of 29 patients affected by toenail onychomycosis, 14 were treated with terbinafine 250 mg/day for 4 months and 15 with griseofulvin 1 g/day for 9 months. In all cases follow-up was 6 months. All four patients with fingernail onychomycosis (100{\%}) and 11 of the 14 patients with toenail onychomycosis (78.5{\%}) treated with terbinafine were completely cured. Two patients with fingernail onychomycosis (40{\%}) and 4 patients with toenail onychomycosis (26.5{\%}) treated with griseofulvin were cured. The successful results obtained with terbinafine, with the absence of concomitant relapses or side effects, suggest this drug as an agent of choice in the treatment of onychomycosis.",
keywords = "griseofulvin, onychomychosis, terbinafine",
author = "{La Placa}, M. and C. Stinchi and N. Venturo and R. Morelli and Antonella Tosti",
year = "1994",
month = "8",
day = "19",
language = "Italian",
volume = "129",
journal = "Giornale Italiano di Dermatologia e Venereologia",
issn = "0392-0488",
publisher = "Edizioni Minerva Medica S.p.A.",
number = "4",

}

TY - JOUR

T1 - TERBINAFINE VS GRISEOFULVINA NELLA TERAPIA DELLE ONICOMICOSI DA DERMATOFITI

AU - La Placa, M.

AU - Stinchi, C.

AU - Venturo, N.

AU - Morelli, R.

AU - Tosti, Antonella

PY - 1994/8/19

Y1 - 1994/8/19

N2 - Griseofulvin has been for a long time the only available antifungal agent for the systemic therapy of onychomycosis. However, this drug requires long treatment yielding low success rates and frequent relapses combined with a relatively high incidence of side effects. recently terbinafine, a new antifungal agent which has been shown to be an effective treatment with short-term regimen for onychomycosis, has been introduced in Italy. In a comparative double-blind study the efficacy of terbinafine and griseofulvin in the treatment of onychomycosis bas been evaluated. Out of 9 patients affected by fingernail onychomycosis, 4 were treated with terbinafine at the dosage of 250 mg/day for 2 months and 5 with griseofulvin at the dosage of 1 g/day for 4 months. Of 29 patients affected by toenail onychomycosis, 14 were treated with terbinafine 250 mg/day for 4 months and 15 with griseofulvin 1 g/day for 9 months. In all cases follow-up was 6 months. All four patients with fingernail onychomycosis (100%) and 11 of the 14 patients with toenail onychomycosis (78.5%) treated with terbinafine were completely cured. Two patients with fingernail onychomycosis (40%) and 4 patients with toenail onychomycosis (26.5%) treated with griseofulvin were cured. The successful results obtained with terbinafine, with the absence of concomitant relapses or side effects, suggest this drug as an agent of choice in the treatment of onychomycosis.

AB - Griseofulvin has been for a long time the only available antifungal agent for the systemic therapy of onychomycosis. However, this drug requires long treatment yielding low success rates and frequent relapses combined with a relatively high incidence of side effects. recently terbinafine, a new antifungal agent which has been shown to be an effective treatment with short-term regimen for onychomycosis, has been introduced in Italy. In a comparative double-blind study the efficacy of terbinafine and griseofulvin in the treatment of onychomycosis bas been evaluated. Out of 9 patients affected by fingernail onychomycosis, 4 were treated with terbinafine at the dosage of 250 mg/day for 2 months and 5 with griseofulvin at the dosage of 1 g/day for 4 months. Of 29 patients affected by toenail onychomycosis, 14 were treated with terbinafine 250 mg/day for 4 months and 15 with griseofulvin 1 g/day for 9 months. In all cases follow-up was 6 months. All four patients with fingernail onychomycosis (100%) and 11 of the 14 patients with toenail onychomycosis (78.5%) treated with terbinafine were completely cured. Two patients with fingernail onychomycosis (40%) and 4 patients with toenail onychomycosis (26.5%) treated with griseofulvin were cured. The successful results obtained with terbinafine, with the absence of concomitant relapses or side effects, suggest this drug as an agent of choice in the treatment of onychomycosis.

KW - griseofulvin

KW - onychomychosis

KW - terbinafine

UR - http://www.scopus.com/inward/record.url?scp=0028106597&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028106597&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0028106597

VL - 129

JO - Giornale Italiano di Dermatologia e Venereologia

JF - Giornale Italiano di Dermatologia e Venereologia

SN - 0392-0488

IS - 4

ER -